International Hepatology

 2012 
 2011 
 2010 


2012

  • Sorafenib use while waiting for liver transplant: We still need to wait
    March 2012 (Vol. 56 | No. 3 | Pages 723-725)

    Richard S. Finn

  • A dive into the complexity of type I interferon antiviral functions
    March 2012 (Vol. 56 | No. 3 | Pages 726-728)

    Maxime Touzot, Vassili Soumelis, Tarik Asselah

  • Genomic risk of hepatitis C-related hepatocellular carcinoma
    March 2012 (Vol. 56 | No. 3 | Pages 729-730)

    Yujin Hoshida, Bryan C. Fuchs, Kenneth K. Tanabe

  • Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
    February 2012 (Vol. 56 | No. 2 | Pages 486-487)

    Jairo A. Garcia, Lewis R. Roberts

  • Back to basics: Staging and prognosis in HCC for medical oncologist
    February 2012 (Vol. 56 | No. 2 | Pages 488-489)

    Markus Peck-Radosavljevic

  • EpCAM in hepatocytes and their progenitors
    February 2012 (Vol. 56 | No. 2 | Pages 490-492)

    Olivier Gires

  • Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens
    January 2012 (Vol. 56 | No. 1 | Pages 276-278)

    Alessio Aghemo, Massimo Colombo

  • Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration
    January 2012 (Vol. 56 | No. 1 | Pages 279-281)

    Andreas Teufel, Jens U. Marquardt, Peter R. Galle

  • Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C
    January 2012 (Vol. 56 | No. 1 | Pages 282-284)

    Nikolaus Jilg, Raymond T. Chung

2011

  • The liver X receptor in hepatic stellate cells: A novel antifibrogenic target?
    December 2011 (Vol. 55 | No. 6 | Pages 1452-1454)

    Ariane Mallat, Sophie Lotersztajn

  • Can serotonin agonists unlock age-dependent failure of liver regeneration?
    December 2011 (Vol. 55 | No. 6 | Pages 1455-1456)

    Stephen J. Wigmore

  • Realize the advance in HCV treatment, but remain cautious
    December 2011 (Vol. 55 | No. 6 | Pages 1457-1460)

    Tarik Asselah

  • Early TIPS with covered stents in high-risk patients with cirrhosis presenting with variceal bleeding: Are we ready to dive into the deep end of the pool?
    November 2011 (Vol. 55 | No. 5 | Pages 1148-1149)

    Dominique Thabut, Marika Rudler, Didier Lebrec

  • Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response
    November 2011 (Vol. 55 | No. 5 | Pages 1150-1153)

    Emilie Estrabaud, Simon De Muynck, Tarik Asselah

  • A sprint to increase response to HCV treatment: Expectancies but caution
    November 2011 (Vol. 55 | No. 5 | Pages 1154-1158)

    Tarik Asselah

  • Oral combination therapy: Future hepatitis C virus treatment?
    October 2011 (Vol. 55 | No. 4 | Pages 933-935)

    Christophe Hézode

  • RANTES antagonism: A promising approach to treat chronic liver diseases
    October 2011 (Vol. 55 | No. 4 | Pages 936-938)

    Silvia Affò, Ramón Bataller

  • New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice
    October 2011 (Vol. 55 | No. 4 | Pages 939-940)

    Michel Fausther, Jonathan A. Dranoff

  • A first step towards a mouse model for hepatitis C virus infection containing a human immune system
    September 2011 (Vol. 55 | No. 3 | Pages 718-720)

    Eric Robinet, Thomas F. Baumert

  • TAK1: Another mesh in the NF-κB – JNK controlled network causing hepatocellular carcinoma
    September 2011 (Vol. 55 | No. 3 | Pages 721-723)

    Florian R. Greten

  • Depicting the role of TP53 in hepatocellular carcinoma progression
    September 2011 (Vol. 55 | No. 3 | Pages 724-725)

    Augusto Villanueva, Yujin Hoshida

  • Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?
    August 2011 (Vol. 55 | No. 2 | Pages 483-485)

    Dominique Thabut, Marika Rudler, Géraldine Rousseau, Thierry Poynard

  • The almighty MYC: Orchestrating the micro-RNA universe to generate aggressive liver cancer
    August 2011 (Vol. 55 | No. 2 | Pages 486-487)

    Snorri S. Thorgeirsson

  • Key role of sinusoidal endothelial cells in the triggering of liver regeneration
    August 2011 (Vol. 55 | No. 2 | Pages 488-490)

    Nicolas Moniaux, Jamila Faivre

  • Non-alcoholic fatty liver disease and fructose: Bad for us, better for mice
    July 2011 (Vol. 55 | No. 1 | Pages 218-220)

    Frank A. Anania

  • Ghrelin and fibrogenesis: Relief for a hungry liver
    July 2011 (Vol. 55 | No. 1 | Pages 221-223)

    Fabio Marra

  • Non-invasive diagnostic imaging of hepatocellular carcinoma: Targeting cellular characterization?
    July 2011 (Vol. 55 | No. 1 | Pages 224-226)

    Alain Luciani, Laurence Baranes, Thomas Decaens, Frederic Pigneur, Alexis Laurent, Jeanne Tran-Van Nhieu, Alain Rahmouni

  • Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR
    June 2011 (Vol. 54 | No. 6 | Pages 1307-1309)

    Nicolas Marsollier, Pascal Ferré, Fabienne Foufelle

  • Surveillance for hepatocellular carcinoma in cirrhotic patients: From official recommendations to the real life
    June 2011 (Vol. 54 | No. 6 | Pages 1310-1311)

    Jean-Claude Trinchet

  • Platelets arrive at the scene of fibrosis……studies
    May 2011 (Vol. 54 | No. 5 | Pages 1063-1065)

    Virginia Hernandez-Gea, Scott L. Friedman

  • Drug enhanced autophagy to fight mutant protein overload
    May 2011 (Vol. 54 | No. 5 | Pages 1066-1068)

    Maryam Mehrpour, Patrice Codogno

  • NS5A inhibitors: A new breakthrough for the treatment of chronic hepatitis C
    May 2011 (Vol. 54 | No. 5 | Pages 1069-1072)

    Tarik Asselah

  • Power play: Scoring our goals for liver cancer with better GWAS study design
    April 2011 (Vol. 54 | No. 4 | Pages 823-824)

    Anuradha Budhu, Xin Wei Wang

  • Liver transplantation as a model to better understand the cell entry of hepatitis C virus
    April 2011 (Vol. 54 | No. 4 | Pages 825-826)

    Cyril Féray

  • Combination of gemcitabine and cisplatin for biliary tract cancer: A platform to build on
    March 2011 (Vol. 54 | No. 3 | Pages 577-578)

    Nataliya Razumilava, Gregory J. Gores

  • Abnormal nitrosothiol metabolism in hepatocellular carcinoma
    March 2011 (Vol. 54 | No. 3 | Pages 579-580)

    Juliette Martin, Jean-François Dufour

  • Platelet-derived chemokines: New targets to treat liver fibrosis
    March 2011 (Vol. 54 | No. 3 | Pages 581-583)

    Oriol Morales-Ibanez, Ramón Bataller

  • A reengineered liver for transplantation
    February 2011 (Vol. 54 | No. 2 | Pages 386-387)

    Nicolas Moniaux, Jamila Faivre

  • Insulin resistance and oxidative stress: Two therapeutic targets in non-alcoholic steatohepatitis
    February 2011 (Vol. 54 | No. 2 | Pages 388-391)

    Cosmin Sebastian Voican, Gabriel Perlemuter

  • Inhibition of mammalian target of rapamycin: Two goals with one shot?
    January 2011 (Vol. 54 | No. 1 | Pages 182-183)

    Christopher Soll, Pierre-Alain Clavien

  • Evolving strategies in the diagnosis of hepatocellular carcinoma
    January 2011 (Vol. 54 | No. 1 | Pages 184-186)

    Riccardo Lencioni

  • Microarchitecture of the liver: A Jigsaw puzzle
    January 2011 (Vol. 54 | No. 1 | Pages 187-188)

    Marcos Rojkind, George Philips, Anna Mae Diehl

2010

  • Nonalcoholic fatty liver disease: The hepatic trigger of the metabolic syndrome
    December 2010 (Vol. 53 | No. 6 | Pages 1146-1147)

    Federico Salamone, Elisabetta Bugianesi

  • Hepatitis C virus entry and glucocorticosteroids
    December 2010 (Vol. 53 | No. 6 | Pages 1148-1150)

    Samira Fafi-Kremer, François Habersetzer, Thomas F. Baumert

  • Unraveling the genetic predisposition of ribavirin-induced anaemia
    November 2010 (Vol. 53 | No. 5 | Pages 971-973)

    Tarik Asselah, Eric Pasmant, Saïd Lyoumi

  • A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis
    November 2010 (Vol. 53 | No. 5 | Pages 974-975)

    Junfang Ji, Xin Wei Wang

  • Radiofrequency ablation for the treatment of HCC – Maybe much more than simple tumor destruction?
    October 2010 (Vol. 53 | No. 4 | Pages 775-776)

    Tim F. Greten, Firouzeh Korangy

  • Building a bridge between obesity, inflammation and liver carcinogenesis
    October 2010 (Vol. 53 | No. 4 | Pages 777-779)

    Jean-Charles Nault, Jessica Zucman-Rossi

  • Genomic tracing of the elusive liver cancer ancestor
    September 2010 (Vol. 53 | No. 3 | Pages 578-579)

    Helena Cornellà, Augusto Villanueva

  • Rifaximin in hepatic encephalopathy: More than just a non-absorbable antibiotic?
    September 2010 (Vol. 53 | No. 3 | Pages 580-582)

    Rajiv Jalan

  • Mutation specific drug therapy for progressive familial or benign recurrent intrahepatic cholestasis: A new tool in a near future?
    August 2010 (Vol. 53 | No. 2 | Pages 385-387)

    Emmanuel Gonzales, Emmanuel Jacquemin

  • Getting closer to the patient: Upgrade of hepatitis C virus infection in primary human hepatocytes
    August 2010 (Vol. 53 | No. 2 | Pages 388-389)

    Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert

  • Caffeine, a drug for all seasons
    July 2010 (Vol. 53 | No. 1 | Pages 207-208)

    Bruce N. Cronstein

  • A new life for bile acids
    June 2010 (Vol. 52 | No. 6 | Pages 937-938)

    Peter L.M. Jansen

  • The resurrection of alphafetoprotein
    June 2010 (Vol. 52 | No. 6 | Pages 939-940)

    Morris Sherman

  • Adenosine: Tipping the balance towards hepatic steatosis and fibrosis
    June 2010 (Vol. 52 | No. 6 | Pages 941-943)

    Simon C. Robson, Detlef Schuppan

  • Foxa1 and Foxa2 regulate bile duct development in mice
    May 2010 (Vol. 52 | No. 5 | Pages 765-767)

    Mario Strazzabosco

  • No inflammation? No cancer! Clear HBV early and live happily
    May 2010 (Vol. 52 | No. 5 | Pages 768-770)

    Erica Villa, Giovanna Fattovich

  • Serological Surveillance for hepatocellular carcinoma: Time to quit
    April 2010 (Vol. 52 | No. 4 | Pages 614-615)

    M. Sherman

  • International Hepatology
    March 2010 (Vol. 52 | No. 3 | Pages 450-451)

    Shannon S. Glaser, Gianfranco Alpini

  • Genetic polymorphism and response to treatment in chronic hepatitis C: The future of personalized medicine
    March 2010 (Vol. 52 | No. 3 | Pages 452-454)

    Tarik Asselah

  • EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
    February 2010 (Vol. 52 | No. 2 | Pages 280-281)

    Benoit Terris, Catherine Cavard, Christine Perret

  • CD8+ T cells drive adipose tissue inflammation – A novel clue for NASH pathogenesis?
    January 2010 (Vol. 52 | No. 1 | Pages 130-132)

    Yury Popov, Detlef Schuppan

  • PEG IFN alfa-2a vs. alfa-2b: And the winner is …?
    January 2010 (Vol. 52 | No. 1 | Pages 133-135)

    Antonio Craxì